: Advances in genomics have the potential to improve the delivery of health care by targeting interventions to individuals who will receive the greatest benefit and experience the lowest risk of adverse events. More effective targeting of interventions is particularly appealing because it is one of the few approaches that can both improve outcomes and reduce costs- the unquestioned sweet spot of health care reform. However, genomic medicine has a long way to go before it gets to that sweet spot. Some of what is needed is discovery of gene-disease associations that lead to the development of a clinical genetic test. But increasingly, the needs lie not in developing the test but in deciding whether using the test is better than doing what we are currently doing - i.e. comparative effectiveness. The overarching goal of this project is to develop a coordinated, multidisciplinary center for the generation and synthesis of evidence to support the translation of genomic tests into improvements in cancer prevention, screening, diagnosis, treatment and survivorship. The center (entitled the Center for Comparative Effectiveness in Genomic Medicine or CCEGM) will involve two primary scientific components: (1) evidence generation;and (2) evidence synthesis and modeling. The goal of the evidence generation component is to conduct observational and experimental studies of the comparative effectiveness of genomic test that are clinically available or nearly clinically available. Four proof of principle, pilot studies are included in this proposal: (1) pharmacogenomics of nicotine addiction treatment;(2) incremental information from breast cancer SNP panels in breast cancer risk screening and prevention;(3) personalized treatment for non small cell lung cancer;and (4) CDKN2A/p16 testing and adherence to melanoma prevention behaviors. The goal of the evidence synthesis component is to use statistical and modeling methods to bring together existing evidence to inform recommendations about clinical practice. Three corresponding evidence synthesis pilot projects are included: a systematic review of the clinical validity of EGFr and K-ras mutations in predicting response to treatment, a decision model of the use of SNP panels in breast cancer screening, a cost- effectiveness model of nicotine metabolism markers in treatment of nicotine addiction.
Advances in genomics have the potential to improve the delivery of health care. Increasingly, there is a need to decide whether the use of genomic tests is better than doing what we are currently doing - i.e. comparative effectiveness. The overarching goal of this project is to develop a coordinated, multidisciplinary center for the generation and synthesis of evidence to support the translation of genomic tests into improvements in cancer prevention, screening, diagnosis, treatment and survivorship.
|McCarthy, Anne Marie; Keller, Brad; Kontos, Despina et al. (2015) The use of the Gail model, body mass index and SNPs to predict breast cancer among women with abnormal (BI-RADS 4) mammograms. Breast Cancer Res 17:1|
|Keller, Brad M; McCarthy, Anne Marie; Chen, Jinbo et al. (2015) Associations between breast density and a panel of single nucleotide polymorphisms linked to breast cancer risk: a cohort study with digital mammography. BMC Cancer 15:143|
|Glanz, Karen; Volpicelli, Kathryn; Jepson, Christopher et al. (2015) Effects of tailored risk communications for skin cancer prevention and detection: the PennSCAPE randomized trial. Cancer Epidemiol Biomarkers Prev 24:415-21|
|Bekelman, Justin E; Mitra, Nandita; Handorf, Elizabeth A et al. (2015) Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. J Clin Oncol 33:716-22|
|Bauml, Joshua; Mick, Rosemarie; Zhang, Yu et al. (2013) Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies. Clin Lung Cancer 14:581-91|
|Glanz, Karen; Volpicelli, Kathryn; Kanetsky, Peter A et al. (2013) Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Cancer Epidemiol Biomarkers Prev 22:607-14|
|Bekelman, Justin E; Handorf, Elizabeth A; Guzzo, Thomas et al. (2013) Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research. Value Health 16:610-8|
|McCarthy, Anne Marie; Armstrong, Katrina; Handorf, Elizabeth et al. (2013) Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women. Breast Cancer Res Treat 138:889-98|
|Armstrong, Katrina; Handorf, Elizabeth A; Chen, Jinbo et al. (2013) Breast cancer risk prediction and mammography biopsy decisions: a model-based study. Am J Prev Med 44:15-22|
|Bauml, Joshua; Mick, Rosemarie; Zhang, Yu et al. (2013) Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? Lung Cancer 81:347-53|
Showing the most recent 10 out of 17 publications